ELK1 and non-small cell lung carcinoma: We also identified ELK1 as an upstream factor of the canonical MTOR–S6K1 axis and found that overactivation of the ELK1/MTOR/S6K1 pathway contributes to the development of gefitinib resistance in NSCLC.